Haemonetics Acquires Vivasure Medical for Up to €185 Million in Vessel Closure Deal

Haemonetics Corporation announced on Friday, January 9, that it has acquired Vivasure Medical, a Galway, Ireland, company that makes a patch-based system for closing large holes made in arteries and veins during catheter procedures, in a release distributed by PR Newswire. The deal includes €100 million in upfront cash and up to €85 million more in contingent consideration.

The upfront payment comes to about €52 million net of the value of earlier investments and loans Haemonetics had made to Vivasure, along with customary closing adjustments, the company said. The contingent payments depend on sales growth and other milestones. Haemonetics said it paid for the transaction with cash on hand.

MedTech Dive converted the upfront payment to $116.3 million.

The PerQseal Elite system

Vivasure's PerQseal Elite uses a proprietary bioabsorbable patch to seal large-bore arteriotomies and venotomies of up to 26 French from inside the vessel, according to the release. Haemonetics described it as a sutureless, fully absorbable option for structural heart and endovascular procedures.

In 2025, Vivasure submitted a premarket approval application to the FDA for the arterial closure system and received CE marking in Europe for both arterial and venous use, the company said. PerQseal and PerQseal Elite are not available for sale in the United States.

Haemonetics cited results from ELITE, a prospective, single-arm, multicenter arterial study. The company reported no major vascular complications at 30-day follow-up in the per-protocol population and an immediate median time to hemostasis. Those results come from the company's release.

"Acquiring Vivasure expands Haemonetics' complete range of closure devices with new and clinically differentiated technology to bolster our presence in the large-bore closure market and our impact in fast-growing structural heart and endovascular procedures," said Ken Crowley, vice president and general manager of interventional technologies at Haemonetics.

Andrew Glass, Vivasure's chief executive, said joining Haemonetics "provides the global scale and resources to accelerate the availability of PerQseal Elite and bring its clinical benefits to more physicians and patients worldwide."

A $300 million market with one US approval

Needham analyst Mike Matson wrote in a note to clients that Vivasure's system should complement Haemonetics' existing devices and let the company extend its vascular closure range into larger-bore procedures such as transcatheter aortic valve replacement and endovascular aortic aneurysm repair, MedTech Dive reported.

Haemonetics estimates the total available market for large-bore closure at $300 million, Matson wrote. He said Teleflex's Manta is the only FDA-approved large-bore closure device in the US market, and that he expects competition to rise as other companies, such as Cordis, prepare to enter.

The deal follows other Haemonetics acquisitions aimed at heart procedures. The company bought Attune Medical, which makes a device to protect the esophagus during cardiac ablation, in 2024, and Cardiva Medical, a maker of vascular closure systems, in 2021, according to MedTech Dive.

Vivasure runs research and development and ISO 13485-certified manufacturing in Galway, according to the release.